Debevoise is Advising TPG Capital and Adare Pharmaceuticals in the Sale of Adare Pharmaceuticals

23 September 2020

Debevoise & Plimpton LLP is advising TPG Capital LLC and Adare Pharmaceuticals Inc., in the sale of Adare Pharmaceuticals, a leading specialty contract development and manufacturing organization. For more information, please see the company’s press release.

TPG is a leading global alternative asset firm with approximately $83 billion of assets under management. TPG's investment platforms are across a wide range of asset classes, including private equity, growth equity, real estate, and public equity. Adare Pharmaceuticals is a leading specialty contract development and manufacturing organization (CDMO) and a leading global provider of advanced pharmaceutical technologies, development, and manufacturing.

The Debevoise team is led by M&A partner Andrew Bab and includes M&A counsel Philippe Tengelmann and associates Joshua Allen, Erik Andren, Lauren Beasley, Mihai Chitulescu, Benjamin Collins-Wood, Nathan Frost, Michelle Guo, Rosanne Lariven and Alexander Smith, finance partner Jeffrey Ross and associates Wesley Moore, Ryan Rafferty and Brad Taylor, Luxembourg partner Christopher Dortschy and associate Mathieu Voos, benefits partners Meir Katz and Jon Lewis and associates David Deutsch and Douglas Hirn, tax partner Gary Friedman and associate Samuel Krawiecz, intellectual property partner Henry Lebowitz and associate Jason LeBlanc, FDA regulatory partner Paul Rubin and associate Melissa Runsten and environmental counsel Stuart Hammer.